Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
AI Stocks Slide ðĐ Dell āļāļīāđāļ 11% āļŦāļĨāļąāļāđāļĢāļāļāļēāļĒāļāļĨāđāļĄāļŦāļļāđāļ AI
Micron vs. Nvidia: āļāļēāļ§āļĢāļļāđāļ AI āļĢāļēāļĒāđāļŦāļĄāđāļāļāļ Wall Street āļāļļāđāļ 18 āđāļāđāļēāļŦāļĨāļąāļāļĒāļļāļ ChatGPT
Morgan Stanley āđāļāļ§āđāļāļāđāļāļĢāļĄāļēāļŠāļŠāļļāļāđāļāļĢāđāļ āļāļģāđāļĢāļāļļāļāļŠāļāļīāļāļī āļŦāļāļļāļ Wall Street Rally
āļŦāļļāđāļ BlackRock āļāļļāđāļ 5% āļŦāļĨāļąāļāļāļĢāļ°āļāļēāļĻāļāļ ðž āļ§āļāļĨāļĨāđāļŠāļāļĢāļĩāļāļĢāļēāļĒāļāļēāļāļāļ°āđāļĢāļāđāļēāļ?
